eli lilly - Search News

News

Mounjaro, Eli Lilly and Trulicity

Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a large,

CNBC on MSN · 1d

Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.

PharmExec · 18h

Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 diabetes patients.

11h

Eli Lilly: The Best Growth Prospects Come At A Price

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

6hon MSN

Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

11h

Big Banks slump, UnitedHealth's new CFO, Eli Lilly & Novo rise

Yahoo Finance anchor Julie Hyman tracks Friday's top moving stocks and biggest market stories in this Market Minute. Big Bank ...

Trim Your AI Stocks And Buy Eli Lilly

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

10hon MSN

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

Eli Lilly’s best-selling diabetes drug Mounjaro lowered the risk of heart attacks and stroke in a late-stage trial, the ...

15h

Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage

Eli Lilly (NYSE:LLY) stock rose 1.3% and Novo Nordisk (NYSE:NVO) shares jumped 2% Friday morning after The Washington Post reported that Medicare and Medicaid programs are planning to experiment with ...

16h

Eli Lilly: The Worst May Be Already Over (Earnings Preview)

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.